Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Journal of Molecular Biology
|
July 27, 2010
Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine
Robert D Fisher, Mark Ultsch, Andreas Lingel, et al.
Plos One
|
January 4, 2013
Reorienting the Fab domains of trastuzumab results in potent HER2 activators
Justin M Scheer, Wendy Sandoval, J Michael Elliott, et al.
Nature Communications
|
September 8, 2016
High cell-surface density of HER2 deforms cell membranes
Inhee Chung, Mike Reichelt, Lily Shao, et al.
The Journal of Biological Chemistry
|
November 21, 2022
Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action
Jocelyn Chan, Joyce Chan, Lily Shao, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
February 11, 2026
Characterization of an anti-STEAP1 T-Cell Dependent Bispecific Antibody for the Treatment of Prostate Cancer and Associated Toxicity in Cynomolgus Monkeys
Elizabeth G Tonkin, Michelle Lepherd, John Davies, et al.
Cancer Discovery
|
December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790M
Ho-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Science Translational Medicine
|
February 8, 2013
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer
Ganapati V Hegde, Cecile C de la Cruz, Cecilia Chiu, et al.
Plos One
|
October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Plos One
|
January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Cancer Cell
|
October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
Gabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Journal of Molecular Biology
|
July 27, 2010
Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine
Robert D Fisher, Mark Ultsch, Andreas Lingel, et al.
Plos One
|
January 4, 2013
Reorienting the Fab domains of trastuzumab results in potent HER2 activators
Justin M Scheer, Wendy Sandoval, J Michael Elliott, et al.
Nature Communications
|
September 8, 2016
High cell-surface density of HER2 deforms cell membranes
Inhee Chung, Mike Reichelt, Lily Shao, et al.
The Journal of Biological Chemistry
|
November 21, 2022
Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action
Jocelyn Chan, Joyce Chan, Lily Shao, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
February 11, 2026
Characterization of an anti-STEAP1 T-Cell Dependent Bispecific Antibody for the Treatment of Prostate Cancer and Associated Toxicity in Cynomolgus Monkeys
Elizabeth G Tonkin, Michelle Lepherd, John Davies, et al.
Cancer Discovery
|
December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790M
Ho-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Science Translational Medicine
|
February 8, 2013
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer
Ganapati V Hegde, Cecile C de la Cruz, Cecilia Chiu, et al.
Plos One
|
October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Plos One
|
January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Cancer Cell
|
October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
Gabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Page
of 2